Subsequent Events	9 Months Ended
Sep. 30, 2023
Subsequent Events
Subsequent Events	13. Subsequent Events The Company has evaluated subsequent events through November 14, 2023, the date on which the accompanying financial statements were issued and concluded that no subsequent events have occurred that require disclosure except as noted below or in Note 10. *PET Labs Share Purchase Agreement* In October 2023, ASP Isotopes Inc. entered into a Share Purchase Agreement (“SPA”) with Nucleonics Imaging Proprietary Limited (“Nucleonics”), a company incorporated in South Africa, to purchase ordinary shares in Nucleonics’ wholly-owned subsidiary, Pet Labs Pharmaceuticals Proprietary Limited (“PET Labs”), a company incorporated in South Africa and dedicated to nuclear medicine and the science of radiopharmaceutical production. Per the SPA, ASP Isotopes Inc. has agreed to purchase from Nucleonics 51% of the issued share capital of PET Labs (“Initial Shares”) ASP Isotopes Inc. will pay a total of $2,000,000 for the Initial Shares in two instalments. The first instalment of $500,000 was paid in November 2023. The second instalment of $1,500,000 is payable upon demand by Necleonics after October 27, 2024. In addition, ASP Isotopes Inc. has an option to purchase from Nucleonics the remaining 49% of the issued share capital of PET Labs (“Option Shares”) that expires on January 31, 2027. The option is only exercisable if the Initial Shares have been paid in full. Upon ASP Isotopes Inc. exercising its option to purchase the Option Shares ASP Isotopes has agreed to pay an additional $2,200,000 to Nucleonics. As of the date on which the accompanying financial statements were issued, the Company is still evaluating the accounting and financial reporting requirements of this transaction.

Subsequent Events

9 Months Ended

Sep. 30, 2023

13. Subsequent Events

The Company has evaluated subsequent events through November 14, 2023, the date on which the accompanying financial statements were issued and concluded that no subsequent events have occurred that require disclosure except as noted below or in Note 10.

PET Labs Share Purchase Agreement

In October 2023, ASP Isotopes Inc. entered into a Share Purchase Agreement (“SPA”) with Nucleonics Imaging Proprietary Limited (“Nucleonics”), a company incorporated in South Africa, to purchase ordinary shares in Nucleonics’ wholly-owned subsidiary, Pet Labs Pharmaceuticals Proprietary Limited (“PET Labs”), a company incorporated in South Africa and dedicated to nuclear medicine and the science of radiopharmaceutical production.

Per the SPA, ASP Isotopes Inc. has agreed to purchase from Nucleonics 51% of the issued share capital of PET Labs (“Initial Shares”) ASP Isotopes Inc. will pay a total of $2,000,000 for the Initial Shares in two instalments. The first instalment of $500,000 was paid in November 2023. The second instalment of $1,500,000 is payable upon demand by Necleonics after October 27, 2024.

In addition, ASP Isotopes Inc. has an option to purchase from Nucleonics the remaining 49% of the issued share capital of PET Labs (“Option Shares”) that expires on January 31, 2027. The option is only exercisable if the Initial Shares have been paid in full. Upon ASP Isotopes Inc. exercising its option to purchase the Option Shares ASP Isotopes has agreed to pay an additional $2,200,000 to Nucleonics.

As of the date on which the accompanying financial statements were issued, the Company is still evaluating the accounting and financial reporting requirements of this transaction.